Price$3.70-0.08 (-2.12%)
01:30 PM07:15 PM
News · 26 weeks70+71%
2026-01-182026-07-12
Mix3990d
- Insider16(41%)
- Other11(28%)
- SEC Filings8(21%)
- Earnings2(5%)
- Leadership1(3%)
- Dividends1(3%)
Latest news
25 items- PRPlus Therapeutics and Genomic Testing Cooperative Partner to Integrate Next-Generation Sequencing Into the CNSide® CSF Assay PlatformHOUSTON and LAKE FOREST, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) ("Plus" or the "Company") and Genomic Testing Cooperative, LCA ("GTC") today announced a collaboration to integrate GTC’s next-generation sequencing (NGS) technology into the CNSide® cerebrospinal fluid (CSF) assay platform. The collaboration is expected to enable comprehensive DNA and RNA profiling across hundreds of clinically relevant biomarkers from a single CSF specimen, extending CNSide from guideline-recognized CTC enumeration into the guideline-recognized DNA and tumor-derived DNA analytic layer within one integrated platform. The collaboration advances Plus’ three-pillar CNS on
- PRPlus Therapeutics Highlights NCCN CNS Cancers Guidelines Update and Reinforces Clinical Role of CNSide® in Leptomeningeal Metastases MonitoringHOUSTON, July 14, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) ("Plus" or the "Company"), today highlighted the recent update to the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Central Nervous System Cancers, including guidance relevant to leptomeningeal metastases (LM), a serious and often underdiagnosed complication of advanced cancer. The updated NCCN CNS Cancers Guidelines reinforce that cerebrospinal fluid (CSF) analysis remains a standard component of LM diagnosis and disease assessment and that, in patients receiving intrathecal therapy, CSF cytology is typically re-evaluated every four to eight weeks alongside MRI a
- INSIDERDirector Andrews Ronald Asbury converted options into 922 shares (SEC Form 4)4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)
- INSIDERChief Financial Officer Sims Andrew John Hugh Macintyre converted options into 2,985 shares, increasing direct ownership by 43% to 9,941 units (SEC Form 4)4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)
- INSIDERDirector Hawkins Richard J converted options into 922 shares, increasing direct ownership by 152% to 1,529 units (SEC Form 4)4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)
- INSIDERDirector Van Es-Johansson An converted options into 922 shares (SEC Form 4)4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)
- INSIDERDirector Clowes Howard converted options into 922 shares, increasing direct ownership by 87% to 1,981 units (SEC Form 4)4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)
- INSIDERChief Executive Officer Hedrick Marc H converted options into 16,439 shares, increasing direct ownership by 59% to 44,483 units (SEC Form 4)4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)
- INSIDERDirector Guse Kyle converted options into 922 shares (SEC Form 4)4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)
- PRPlus Therapeutics Provides Mid-Year Business Update Including Corporate RebrandingPlus Therapeutics to become Cerenome, to trade under new Nasdaq ticker CNSY on August 3, 2026 Affirms 2026 guidance on key milestones Reports positive CNSide® commercial progress HOUSTON, June 30, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) ("Plus" or the "Company"), a healthcare company focused on central nervous system ("CNS") cancers, today provides a comprehensive business update. Notably, the Company announces it is changing its company name from Plus Therapeutics to Cerenome and Nasdaq ticker to CNSY, effective August 3, 2026. Furthermore, the Company affirmed its anticipated 2026 milestones guidance, including commercial guidance around its CNSide Diagnostics
- PRPlus Therapeutics Secures National Coverage Agreement with Elevance Health for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS CancerHOUSTON, June 25, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), announced today that it has signed a national agreement with Elevance Health, Inc. (NYSE: ELV), effective May 1, 2026, covering approximately 45.4 million people throughout the United States, to provide the CNSide® Cerebrospinal Fluid (CSF) Tumor Cell Enumeration (TCE) assay. This brings CNSide CSF TCE assay total contracted coverage to 126 million people. The CNSide® CSF Assay Platform supports rapid diagnoses, treatment monitoring, and treatment guidance for patients with leptomeningeal metastases. The superior clinical utilit
- PRPlus Therapeutics to Provide Business Update Call on June 30, 2026HOUSTON, June 23, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) ("Plus" or the "Company"), a healthcare company focused on central nervous system ("CNS") cancers, today announced that management will host a business update conference call and webcast on Tuesday, June 30, 2026, at 8:30 a.m. Eastern Time. During the call, management will focus on the Company’s CNSide® diagnostic launch and its integrated development plan for lead drug Reyobiq. Furthermore, management will provide further detail on its CNS oncology strategy and native artificial intelligence development plans. "Our team is making substantial progress in all 3 areas of the company, specifically diagnostics,
- SECSEC Form S-8 filed by PLUS THERAPEUTICS Inc.S-8 - PLUS THERAPEUTICS, INC. (0001095981) (Filer)
- SECSEC Form EFFECT filed by PLUS THERAPEUTICS Inc.EFFECT - PLUS THERAPEUTICS, INC. (0001095981) (Filer)
- SECPLUS THERAPEUTICS Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - PLUS THERAPEUTICS, INC. (0001095981) (Filer)
- SECAmendment: SEC Form S-3/A filed by PLUS THERAPEUTICS Inc.S-3/A - PLUS THERAPEUTICS, INC. (0001095981) (Filer)
- PRPlus Therapeutics Announces CAP Accreditation of CNSide® Diagnostics Clinical LaboratoryHOUSTON, June 04, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly owned subsidiary of Plus Therapeutics, Inc. (NASDAQ:PSTV) ("Plus" or the "Company"), a healthcare company advancing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announces that its Houston-based clinical laboratory has received accreditation from the College of American Pathologists (CAP) following a recent on-site inspection conducted under the CAP Laboratory Accreditation Program. The CAP Laboratory Accreditation Program is internationally recognized as the "gold standard" in laboratory accreditation. As part of this distinction, CNSide Diagnostics' laboratory un
- SECSEC Form S-3 filed by PLUS THERAPEUTICS Inc.S-3 - PLUS THERAPEUTICS, INC. (0001095981) (Filer)
- PRPlus' CNSide Diagnostic Platform Demonstrates Substantial Healthcare Cost Reduction in Patients with Leptomeningeal MetastasesPlus and Harvard analysis shows CNSide enables early diagnosis and better clinical decision-making reducing healthcare costs by 40% Presentation receives blue-ribbon recognition at the ISPOR Annual Meeting, the premier global gathering for health economics and outcomes research HOUSTON, May 26, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) ("Plus" or the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announced the presentation of a new health economics study evaluating the economic impact of earlier detection and therapeutic management of LM using the CNSide ce
- PRPlus Therapeutics Partners with Ephemeral Technologies to Deploy AI Execution Platform for CNS OncologyPartnership to deliver a novel AI-native integrated CNS oncology platform Platform will unify and analyze Plus' proprietary therapeutic, diagnostic, and bioinformatics datasets to accelerate precision neuro-oncology HOUSTON, May 19, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics for central nervous system (CNS) cancers, today announces that it has signed an agreement to enter into a strategic partnership with Ephemeral Technologies ("Ephemeral") to deliver a unique AI execution platform for CNS oncology. The AI execution platform is designed to integrate, organize, and derive ac
- INSIDERSEC Form 4 filed by Director Van Es-Johansson An4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)
- INSIDERSEC Form 4 filed by Director Hawkins Richard J4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)
- INSIDERSEC Form 4 filed by Director Guse Kyle4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)
- INSIDERSEC Form 4 filed by Director Clowes Howard4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)
- INSIDERSEC Form 4 filed by Director Andrews Ronald Asbury4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)
PSTV FAQ
6 questionsWhat does PLUS THERAPEUTICS Inc. do?
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium NanoLiposomes, a patented radiotherapy for patients with recurrent glioblastoma, which is in the Phase 1 dose-finding clinical trial. The company is also developing DocePLUS, a patented chemotherapy for patients with solid tumors that is in Phase 1 clinical trial; and DoxoPLUS, a generic chemotherapy for patients with ovarian cancer. It has a license agreement with NanoTx...Where does PSTV stock trade?
PLUS THERAPEUTICS Inc. (PSTV) is listed on NASDAQ.What sector and industry is PSTV in?
PLUS THERAPEUTICS Inc. operates in the Health Care sector, Medical/Dental Instruments industry.What are analysts saying about PSTV?
PLUS THERAPEUTICS Inc. has had 3 recent analyst actions on file. The most recent action was from Lake Street: Buy with a $200.00 price target on 2026-02-03. Recent price targets range from $200.00 to $900.00.What companies are similar to PSTV?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), MDLN (Medline Inc.), BDX (Becton Dickinson and Company). Compare PSTV side-by-side with any of them on Quantisnow.How can I track PSTV on Quantisnow?
Quantisnow aggregates PLUS THERAPEUTICS Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PSTV to receive live email and push alerts on every new disclosure.